CMDh lets RMS start MR/DC procedures despite silent CMS: what trial sponsors should note

What happened

Austria's medicines agency BASG reported on its RMS newsticker that the CMDh has revised its validation advice for mutual recognition (MR) and decentralised (DC) procedures. According to BASG, a reference member state (RMS) can now start a procedure even when concerned member states (CMS) have not answered its validation queries.

BASG also says the CMDh has updated its RMS request templates. It has flagged which national requirements actually block the start of a procedure. The newsticker summary does not give the full text of the revised advice. It does not say which national requirements fall on either side of that line, or from what date the changes apply. Teams should read the CMDh documents themselves before changing any process.

Why a clinical trials desk should care

MR and DC procedures are marketing authorisation routes, not clinical trial routes. Nothing in the record concerns trial authorisation under the clinical trials framework. The link is downstream. The clinical development programme, the dossier built from it, and the submission timetable are all planned together. Any friction at the start of an MR/DC procedure affects when the evidence generated in trials can be reviewed.

The change targets a specific kind of delay. In these procedures, the RMS checks that an application is valid before the assessment clock starts. If concerned states have to confirm that validation queries are resolved, a slow or silent state can hold up the start for everyone. The revised advice, as BASG describes it, reduces that dependency. Whether it shortens real-world timelines is not yet known, and the record offers no data on it.

Regulatory context

The CMDh is the EU coordination group for MR and DC procedures. Its guidance shapes how national agencies handle validation, and it makes the RMS's role clearer when national practice differs. Flagging which national requirements are start-blocking is useful in itself. Applicants often meet national-specific demands, such as local forms, translations or fees. These can look like preconditions but may not legally prevent a procedure from starting.

That is a reading of the BASG summary, not a statement of the CMDh's text. The distinction between blocking and non-blocking requirements is exactly what regulatory teams need to see in the original wording.

Two other items from the same week show the clinical-operations side of the EU picture. The ŠÚKL in Slovakia reports that the ACT EU pre-submission advice pilot for clinical trial applications will become permanent in January 2027. A final report on about 30 applications is due by the end of 2026. Separately, the EMA has published a notice to sponsors on validating computerised systems used in clinical trials. The information available does not set out its details, so sponsors should read the document itself.

Who is affected

The most directly affected are regulatory affairs teams that run, or plan to run, MR/DC submissions. These include companies seeking multi-country approval for generics, line extensions or products with a clinical programme behind them. Clinical operations teams feel it indirectly, because the timing of the dossier determines when trial deliverables such as clinical study reports and datasets are needed in final form.

Small and mid-sized sponsors may notice it most. A company like Processa Pharmaceuticals, which has just received US IND clearance for a Phase 2 study of its oral BTK inhibitor VT-7208 in urticaria, is a long way from an EU marketing application. Early-stage sponsors do not need to act today, but they should keep the route in mind when choosing a regulatory pathway.

Site and equipment issues are a separate matter. Health Canada's Type II recall of several Philips Azurion 7 configurations, over power supply failures at start-up, has no link to the CMDh change. It is a reminder that operational risks at sites sit in a different category from procedural ones, and both need tracking.

What to watch

First, the primary documents: the revised CMDh validation advice and the updated RMS request templates. Teams should compare them with their internal submission checklists. Second, how RMS agencies apply the new approach in practice, including whether any concerned states raise objections to a procedure that started without their validation answers. Third, whether the CMDh or national agencies publish more detail on the list of start-blocking national requirements. Finally, the ACT EU pilot report due by the end of 2026 and the EMA computerised-systems notice are worth following. They bear on trial design and data-system readiness well before any MR/DC filing.